ETHINYL ESTRADIOL for PMDD

Hypothesized mechanism

Ethinyl estradiol acts as an estrogen receptor alpha agonist on ESR1, potentially modulating hormonal pathways implicated in PMDD.

This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.

Source evidence · what the pipeline ingested

These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).

Every source below belongs to this signal’s evidence arm, Pathway insights. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.

• 1Per Open Targets (retrieved 2026-06-16), ETHINYL ESTRADIOL (a Small molecule) is a clinical candidate for PMDD (maximum clinical stage PHASE_3); its mechanism of action is Estrogen receptor alpha agonist on target estrogen receptor 1. Open Targets · mechanistic ↗
• 2In FDA AEMS (the FDA Adverse Event Reporting System, formerly FAERS; retrieved 2026-06-16), 8745 report(s) of ANXIETY were recorded for ETHINYL ESTRADIOL among female patients (of 89338 female reports for ETHINYL ESTRADIOL in the analysed sample). This is a raw adverse-event report count, not a disproportionality statistic or evidence of causation, and is subject to reporting bias and confounding. Read two ways: as a safety consideration, and — because it suggests ETHINYL ESTRADIOL acts on a system relevant to PMDD — as a mechanistic lead for further investigation, not evidence of benefit. AEMS · adverse-event report ↗
• 3In FDA AEMS (the FDA Adverse Event Reporting System, formerly FAERS; retrieved 2026-06-16), 3579 report(s) of DEPRESSION were recorded for ETHINYL ESTRADIOL among female patients (of 89338 female reports for ETHINYL ESTRADIOL in the analysed sample). This is a raw adverse-event report count, not a disproportionality statistic or evidence of causation, and is subject to reporting bias and confounding. Read two ways: as a safety consideration, and — because it suggests ETHINYL ESTRADIOL acts on a system relevant to PMDD — as a mechanistic lead for further investigation, not evidence of benefit. AEMS · adverse-event report ↗
• 4In FDA AEMS (the FDA Adverse Event Reporting System, formerly FAERS; retrieved 2026-06-16), 3527 report(s) of FATIGUE were recorded for ETHINYL ESTRADIOL among female patients (of 89338 female reports for ETHINYL ESTRADIOL in the analysed sample). This is a raw adverse-event report count, not a disproportionality statistic or evidence of causation, and is subject to reporting bias and confounding. Read two ways: as a safety consideration, and — because it suggests ETHINYL ESTRADIOL acts on a system relevant to PMDD — as a mechanistic lead for further investigation, not evidence of benefit. AEMS · adverse-event report ↗

These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.